Industry News
Pharmaceutical Industry News
Bayer has been asked to rein in…
Bayer has been asked to rein in claims that its One A Day Men’s Pre-Conception Health Complete Multivitamin can help boost male fertility after a rival company challenged the German pharma’s marketing push.
F.D.A. Approves New Eli Lilly Weight-Loss Pill, Foundayo
The drug, made by Eli Lilly, could offer a more convenient option for patients who want to avoid injections.
The FDA has approved Lilly’s…
The FDA has approved Lilly’s GLP-1 receptor agonist pill as the first new molecular entity cleared under the regulator’s controversial Commissioner's National Priority Voucher program.
The National Institute for Health…
The National Institute for Health and Care Excellence, which serves as the U.K.’s drug price regulator, has given the green light to Wegovy (semaglutide) as a weekly injection to prevent heart attacks and strokes. The
Evotec has appointed Ashiq Khan,…
Evotec has appointed Ashiq Khan, Ph.D., as chief commercial officer, putting an executive with robotics and artificial intelligence experience in charge of a unit that is central to the company’s recently unveiled transformation plan.
Israel Strikes Tehran Pharmaceutical Plant, Claiming Military Link
Iran’s foreign minister, Abbas Araghchi, said on Tuesday that Israel was “openly and unashamedly bombing pharmaceutical companies.”
Eli Lilly Will Buy a Narcolepsy Drug Developer for $6.3 Billion
Eli Lilly plans to acquire Centessa Pharmaceuticals, which has been conducting a midstage clinical trial of its lead drug.
How the Internet Became the ‘Cookbook’ of the Drug Trade
A baffling overdose death took investigators to the frontier of ultra-potent synthetic drugs. The clues were hauntingly familiar.
“You want to be holistic, but…
“You want to be holistic, but within a particular specialty,” Ardena CEO Jeremie Trochu recently told Fierce about how the CDMO is navigating rough geopolitical waters.
The agency identified 76 cases of…
The agency identified 76 cases of drug-induced liver injury in patients who used Amgen's Tavneos, including eight deaths.
Amid a major corporate overhaul,…
Amid a major corporate overhaul, Novo Nordisk is pruning the ranks at its Bloomington, Indiana, production facility, which contributes to the blockbuster GLP-1 medications Ozempic and Wegovy.
FDA Is Expected to Lift Restriction on Peptides, Heeding RFK Jr.’s Wishes
The peptides, which are increasingly marketed as providing longevity and health benefits, were removed in 2023 from the agency’s list of products that compounding pharmacies can sell.
Irish antibiotic specialist Iterum…
Irish antibiotic specialist Iterum Therapeutics has started winding down its operations, citing limited cash amid the expensive commercialization of its only approved product, Orlynvah.
BASF Pharma Solutions will raise…
BASF Pharma Solutions will raise its prices by up to 20% for its excipients and some of its active pharmaceutical ingredients, effective immediately.
Biogen is bulking up in…
Biogen is bulking up in immunology—and paving the way for its future ambitions in kidney diseases—with an M&A play that immediately adds two ongoing launches to its marketed drugs portfolio.
Uncovering the World’s Newest and Deadliest Drugs
Overdose rates in the United States have surged with the emergence of new synthetic drugs. Matt Richtel reports from a lab in Pennsylvania where scientists are identifying new drug molecules that toxicology reports can’t detect.
Insulet has reinstated the chief…
Insulet has reinstated the chief commercial officer position three years after eliminating the role to pursue more focused regional and local market execution.
The FDA has delayed its target…
The FDA has delayed its target decision date for Orca Bio’s blood cancer cell therapy candidate Orca-T by three months to July 6 after the company submitted additional CMC-related data.
AI can speed content creation, but…
AI can speed content creation, but human judgment drives credibility, context and behavior change in medical communications.
The company is looking to work out…
The company is looking to work out an arrangement with the U.K. government that would see higher drug prices in exchange for Lilly to continue its U.K. investments, according to a report in The Financial